IQVIA management check

IQV · Health Care · Life Sciences Tools & Services · CEO Ari Bousbib

Filings as of

71
Management score, ranked 168th of 487 · 19th of 60 in Health Care4 good · 2 to watch · 1 flaggedStrongest: stable leadership · Weakest: owner returns · Best and worst run in Health Care →

The seven checks

  • Flag

    Have owners done well?

    Trailed its chosen peersOwners$126Peers$187

    What $100 became since fiscal 2021

    922nd
    Detail

    $100 invested at the start of fiscal 2021 grew to $126, against $187 for the peer group the company picked itself.

  • Good

    Does pay follow performance?

    Pay rose and fell with returns20212025

    Pay actually paid $100 value, each on its own scale

    9997th
    Detail

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.99 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Watch

    What does the CEO cost owners?

    2.1% of net income

    $28.1m pay · $1.4bn net income, FY2025

    0.1%1%3%10%
    2428th
    Detail

    $28.1m of reported pay in fiscal 2025, against $1.4bn of net income.

  • Watch

    Do they own the stock?

    Insiders are selling

    6 mo: ▲ $0 bought · ▼ $31.1m sold

    ——
    Detail

    6 insiders sold $31.1m in the last six months and none bought.

  • Good

    Are owners being diluted?

    Share count shrinking2021 · 195m2025 · 174m

    Diluted shares −3.5% a year; flagged above +2%

    0%10%20%

    Stock pay 1.5% of revenue

    9483rd
    Detail

    Diluted shares changed -3.5% a year over the last three fiscal years. Stock-based pay was 1.5% of revenue in the latest year.

  • Good

    Is leadership stable?

    4 leadership filings in 3 years

    4 filings under 8-K 5.02 in 3 years

    0101420+

    CEO: Ari Bousbib

    100100th
    Detail

    CEO in the pay table: Ari Bousbib. 4 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Good

    Are the books clean?

    No red flags on file

    Since 2021

    • 0Restated
    • 0Auditor changes
    • 0Late filings
    • 010-K amended
    100100th
    Detail

    No restatements, auditor changes or late filings since 2021.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed February 27, 2026.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
$0$44.2m$88.4m$10020212022202320242025$126$187

Pay tied most to Adjusted Diluted EPS Growth

Other key measuresAdjusted Diluted EPS Growth (as defined in “Compensation Discussion and Analysis—Elements of Compensation—Short-Term Incentive Awards,” described on page 57)Relative Total Stockholder Return (as defined in “Compensation Discussion and Analysis—Elements of Compensation— Long-Term Incentive Awards,” described on page 60)Revenue (as defined in “Compensation Discussion and Analysis—Elements of Compensation—Short-Term Incentive Awards,” described on page 57)Adjusted EBITDA (as defined in “Compensation Discussion and Analysis—Elements of Compensation—Short-Term Incentive Awards,” described on page 57)

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025Ari Bousbib$28.1m$36.1m$8.9m$126$187$1.4bn
2024—$26.7m$11.5m$6.6m$110$159$1.4bn
2023—$29.2m$42.3m$4.5m$129$148$1.4bn
2022—$30.1m$6.0m$5.0m$114$138$1.1bn
2021—$28.6m$88.4m$4.4m$157$136$966.0m

Insiders and the CEO's stakeSelling

6 insiders sold $31.1m in the last six months and none bought.

Open-market trades by officers and directors since May 21, 2026.

  • SoldAri BousbibSee Remarks$26.1mJul 29, 2026
  • SoldEric SherbetSee Remarks$2.5mNov 9, 2026
  • SoldW Richard StaubSee Remarks$1.3mAug 3, 2026
  • SoldJames G. BerkshireSee Remarks$697kSep 2, 2026

Leadership and governance on file

20222023202420252026Leadership 9Votes 5
All 9 filings

Latest shareholder vote results: Apr 23, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $5.2bn returned to owners in buybacks and dividends, 84% of net income, and $1.0bn of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
$0$686.5m$1.4bn20212022202320242025Shares195m191m186m183m174m
Show the figures
Fiscal year20212022202320242025
Revenue$13.9bn$14.4bn$15.0bn$15.4bn$16.3bn
Net income$966.0m$1.1bn$1.4bn$1.4bn$1.4bn
Stock-based pay$170.0m$194.0m$217.0m$206.0m$247.0m
Buybacks$406.0m$1.2bn$992.0m$1.4bn$1.2bn
Dividends—————
Diluted shares195m191m186m183m174m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.